DexCom, Q1
Digest more
April 30 (Reuters) - Medical device maker Dexcom on Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by strong demand for its continuous glucose monitors that track blood sugar levels.
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to Coinbase. Yahoo Finance is not a broker-dealer or ...
Dexcom G7 CGMs contain a complex electronic assembly within a wearable package that stands up to the rigors of everyday activity.
DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years. DexCom is a leader in the continuous glucose ...
Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In this article Shares of Dexcom tumbled almost 40% in ...
“This small thing,” Nick Jonas says while holding the all-new Dexcom G7 Continuous Glucose Monitoring (CGM) system in his hand at the start of the new commercial for Super Bowl LVII. With a snap of his finger, the small G7 monitoring device that ...
They offer investors very different value propositions.
Dexcom experienced it's largest ever technical glitch over the weekend. The company's technology chief acknowledged that Dexcom needs to do better. Dexcom is analyzing its tech infrastructure and working to bolster its communications systems. Dexcom's ...
StockStory.org on MSN
DexCom (NASDAQ:DXCM) exceeds Q1 CY2026 expectations but stock drops
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The company expects the full year’s revenue to be around $5.21 billion, close to analysts’ estimates.